{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:12:06Z","timestamp":1791972726682,"version":"4.3.4"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Current treatment recommendations for resectable or borderline pancreatic carcinoma support upfront surgery and adjuvant therapy. However, neoadjuvant therapy (NT) seems to increase prognosis of pancreatic carcinoma and come to everyone\u2019s attention gradually. Randomized controlled trials offering comparison with the NT are lacking and optimal neoadjuvant treatment regimen still remains uncertain. This study aims to compare both treatment strategies for resectable or borderline resectable pancreatic cancer.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>The PRISMA checklist was used as a guide to systematically review relevant peer-reviewed literature reporting primary data analysis. We searched PubMed, Medline, EMBASE, Cochrane Datebase and related reviews for randomized controlled trials comparing neoadjuvant therapy with surgery first for resectable or borderline resectable pancreatic carcinoma. We estimated relative hazard ratios (HRs) for median overall survival and ratios risks (RRs) for microscopically complete (R0) resection among different neoadjuvant regimens and major complications. We assessed the effects of neoadjuvant therapy on R0 resection rate and median overall survival with Bayesian analysis.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Thirteen eligible articles were included. Eight studies performed comparison neoadjuvant therapy with surgery first, and R0 resection rate was recorded in seven studies. Compared with surgery first, neoadjuvant therapy did increase the R0 resection rate (RR = 1.53, I<jats:sup>2<\/jats:sup> = 0%, P&lt; 0.00001), there was a certain possibility that gemcitabine + cisplatin (Gem+Cis) + Radiotherapy was the most favorable in terms of the fact that there was no significant difference concerning the results from the individual studies. In direct comparison, four studies were included and estimated that Neoadjuvant therapy improved mOS compared with upfront surgery (HR 0.68, 95% CI 0.58\u20130.92; P = 0.012; I<jats:sup>2<\/jats:sup> = 15%), after Bayesian analysis it seemed that regimen with Cisplatin\/ Epirubicin then Gemcitabine\/ Capecitabine (PEXG) was most likely the best with a relatively small sample size. The rate of major surgical complications was available for six studies and ranged from 11% to 56% with neoadjuvant therapy and 11% to 45% with surgery first. There was no significant difference between neoadjuvant therapy and surgery first, also with a high heterogeneity (RR = 0.96, 95%CI = 0.65\u20131.43; P = 0.85; I<jats:sup>2<\/jats:sup> = 46%).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>In conclusion neoadjuvant therapy might offer benefit over up-front surgery. Neoadjuvant therapy increased the R0 resection rate with gemcitabine + cisplatin + Radiotherapy that was the most favorable and improved mOS with Cisplatin\/ Epirubicin then Gemcitabine\/ Capecitabine (PEXG) that was most likely the best.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0295983","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T18:40:26Z","timestamp":1709836826000},"page":"e0295983","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["Comparison of neoadjuvant treatment and surgery first for resectable or borderline resectable pancreatic carcinoma: A systematic review and network meta-analysis of randomized controlled trials"],"prefix":"10.1371","volume":"19","author":[{"given":"Lu","family":"Huan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fucai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hantao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoling","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5965-5138","authenticated-orcid":true,"given":"Yang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"pone.0295983.ref001","first-page":"5","article-title":"Cancer statistics, 2015","volume-title":"CA: a cancer journal for clinicians","author":"R. L. Siegel","year":"2015"},{"key":"pone.0295983.ref002","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012","volume":"49","author":"J. Ferlay","year":"2013","journal-title":"European journal of cancer (Oxford, England: 1990)"},{"key":"pone.0295983.ref003","doi-asserted-by":"crossref","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.","volume":"19","author":"M. A. Tempero","year":"2021","journal-title":"Journal of the National Comprehensive Cancer Network: JNCCN"},{"key":"pone.0295983.ref004","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.pan.2018.09.012","article-title":"Diagnosis and management of pancreatic cancer in adults: A summary of guidelines from the UK National Institute for Health and Care Excellence.","volume":"18","author":"D. O\u2019Reilly","year":"2018","journal-title":"Pancreatology: official journal of the International Association of Pancreatology (IAP)\u2026 [et al.]"},{"key":"pone.0295983.ref005","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"P. van Hagen","year":"2012","journal-title":"The New England journal of medicine"},{"key":"pone.0295983.ref006","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJMoa040694","article-title":"Preoperative versus postoperative chemoradiotherapy for rectal cancer","volume":"351","author":"R. Sauer","year":"2004","journal-title":"The New England journal of medicine"},{"key":"pone.0295983.ref007","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.ijrobp.2008.02.065","article-title":"Neoadjuvant radiation is associated with improved survival in patients with resectable pancreatic cancer: an analysis of data from the surveillance, epidemiology, and end results (SEER) registry.","volume":"72","author":"A. M. Stessin","year":"2008","journal-title":"International journal of radiation oncology, biology, physics"},{"key":"pone.0295983.ref008","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejca.2021.10.023","article-title":"Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials","volume":"160","author":"J. L. van Dam","year":"2022","journal-title":"European journal of cancer (Oxford, England: 1990)"},{"key":"pone.0295983.ref009","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fonc.2020.00041","article-title":"Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer","volume":"10","author":"Q. P. Janssen","year":"2020","journal-title":"Frontiers in oncology"},{"key":"pone.0295983.ref010","article-title":"Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials.","author":"J. M. Cloyd","year":"2020","journal-title":"Journal of clinical medicine 9"},{"key":"pone.0295983.ref011","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.hpb.2020.01.001","article-title":"Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysis","volume":"22","author":"M. Ye","year":"2020","journal-title":"HPB: the official journal of the International Hepato Pancreato Biliary Association"},{"key":"pone.0295983.ref012","doi-asserted-by":"crossref","first-page":"e1000267","DOI":"10.1371\/journal.pmed.1000267","article-title":"Preoperative\/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages","volume":"7","author":"S. Gillen","year":"2010","journal-title":"PLoS medicine"},{"key":"pone.0295983.ref013","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S2468-1253(18)30081-5","article-title":"Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2\u20133 trial","volume":"3","author":"M. Reni","year":"2018","journal-title":"The lancet. Gastroenterology & hepatology"},{"key":"pone.0295983.ref014","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/bjs.10870","article-title":"Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer","volume":"105","author":"E. Versteijne","year":"2018","journal-title":"The British journal of surgery"},{"key":"pone.0295983.ref015","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"D. Moher","year":"2009","journal-title":"BMJ (Clinical research ed.)"},{"key":"pone.0295983.ref016","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"J. P. Higgins","year":"2011","journal-title":"BMJ (Clinical research ed.)"},{"key":"pone.0295983.ref017","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"J. F. Tierney","year":"2007","journal-title":"Trials"},{"key":"pone.0295983.ref018","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/0272989X12455847","article-title":"Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials","volume":"33","author":"S. Dias","year":"2013","journal-title":"Medical decision making: an international journal of the Society for Medical Decision Making"},{"key":"pone.0295983.ref019","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/2046-4053-3-110","article-title":"A Microsoft-Excel-based tool for running and critically appraising network meta-analyses\u2014an overview and application of NetMetaXL","volume":"3","author":"S. Brown","year":"2014","journal-title":"Systematic reviews"},{"key":"pone.0295983.ref020","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"J. P. Higgins","year":"2003","journal-title":"BMJ (Clinical research ed.)"},{"key":"pone.0295983.ref021","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s11605-015-2890-4","article-title":"Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which Failed to Achieve Accrual Targets","volume":"19","author":"R. Casadei","year":"2015","journal-title":"Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract"},{"key":"pone.0295983.ref022","doi-asserted-by":"crossref","first-page":"100485","DOI":"10.1016\/j.esmoop.2022.100485","article-title":"Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical trials","volume":"7","author":"I. Ghanem","year":"2022","journal-title":"ESMO open"},{"key":"pone.0295983.ref023","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00066-014-0737-7","article-title":"Neoadjuvant chemoradiation therapy with gemcitabine\/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial.","volume":"191","author":"H. Golcher","year":"2015","journal-title":"Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft"},{"key":"pone.0295983.ref024","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/SLA.0000000000002705","article-title":"Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2\/3 Trial","volume":"268","author":"J. Y. Jang","year":"2018","journal-title":"Annals of surgery"},{"key":"pone.0295983.ref025","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial.","volume":"8","author":"M. H. G. Katz","year":"2022","journal-title":"JAMA oncology"},{"key":"pone.0295983.ref026","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1245\/s10434-007-9384-x","article-title":"A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin","volume":"14","author":"D. H. Palmer","year":"2007","journal-title":"Annals of surgical oncology"},{"key":"pone.0295983.ref027","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.annonc.2022.09.161","article-title":"Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group.","volume":"34","author":"T. Seufferlein","year":"2023","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology"},{"key":"pone.0295983.ref028","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamaoncol.2020.7328","article-title":"Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial.","volume":"7","author":"D. P. S. Sohal","year":"2021","journal-title":"JAMA oncology"},{"key":"pone.0295983.ref029","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/SLA.0000000000004313","article-title":"Surgical Complications in a Multicenter Randomized Trial Comparing Preoperative Chemoradiotherapy and Immediate Surgery in Patients With Resectable and Borderline Resectable Pancreatic Cancer (PREOPANC Trial).","volume":"275","author":"J. C. van Dongen","year":"2022","journal-title":"Annals of surgery"},{"key":"pone.0295983.ref030","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial.","volume":"40","author":"E. Versteijne","year":"2022","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"pone.0295983.ref031","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/SLA.0000000000005430","article-title":"Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM\/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01).","volume":"275","author":"J. Yamaguchi","year":"2022","journal-title":"Annals of surgery"},{"key":"pone.0295983.ref032","first-page":"3126","article-title":"A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine\/Nab-Paclitaxel in Pancreatic Cancer Patients. Clinical cancer research: an official journal of the","volume":"26","author":"H. J. Zeh","year":"2020","journal-title":"American Association for Cancer Research"},{"key":"pone.0295983.ref033","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13014-019-1330-0","article-title":"Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.","volume":"14","author":"Q. Hu","year":"2019","journal-title":"Radiation oncology (London, England"},{"key":"pone.0295983.ref034","first-page":"323","article-title":"Comparison the efficacy and safety of different neoadjuvant regimens for resectable and borderline resectable pancreatic cancer: a systematic review and network meta-analysis","volume":"79","author":"X. Li","year":"2023","journal-title":"European journal of clinical pharmacology"},{"key":"pone.0295983.ref035","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/SLA.0000000000004131","article-title":"The Complexity of Neoadjuvant Therapy for Operable Pancreatic Cancer: Lessons Learned From SWOG S1505","volume":"272","author":"D. B. Evans","year":"2020","journal-title":"Annals of surgery"},{"key":"pone.0295983.ref036","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1200\/JCO.19.03318","article-title":"Neoadjuvant or Adjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer: Which Is Preferred?","volume":"38","author":"E. M. O\u2019Reilly","year":"2020","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"pone.0295983.ref037","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1245\/s10434-020-09543-x","article-title":"Clinical Implication of Node-negative Resectable Pancreatic Cancer","volume":"28","author":"M. Yamada","year":"2021","journal-title":"Annals of surgical oncology"},{"key":"pone.0295983.ref038","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12893-017-0291-1","article-title":"Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial\u20141 (NorPACT-1))\u2014study protocol for a national multicentre randomized controlled trial.","volume":"17","author":"K. J. Labori","year":"2017","journal-title":"BMC surgery"},{"key":"pone.0295983.ref039","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1186\/s12885-018-4663-4","article-title":"Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy\u2014a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study).","volume":"18","author":"L. Schwarz","year":"2018","journal-title":"BMC cancer"},{"key":"pone.0295983.ref040","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1200\/JCO.2007.15.8634","article-title":"Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head","volume":"26","author":"D. B. Evans","year":"2008","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"pone.0295983.ref041","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.","volume":"389","author":"J. P. Neoptolemos","year":"2017","journal-title":"Lancet (London, England)"},{"key":"pone.0295983.ref042","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer","volume":"379","author":"T. Conroy","year":"2018","journal-title":"The New England journal of medicine"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0295983","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T18:40:54Z","timestamp":1709836854000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0295983"}},"subtitle":[],"editor":[{"given":"Calogero","family":"Cas\u00e0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0295983","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,7]]}}}